Rigopoulou Eirini I, Davies Edward T, Bogdanos Dimitrios-Petrou, Liaskos Christos, Mytilinaiou Maria, Koukoulis George K, Dalekos George N, Vergani Diego
Academic Liver Unit and Research Laboratory of Internal Medicine, Department of Medicine, University of Thessaly, Larissa, Greece.
Liver Int. 2007 Nov;27(9):1226-31. doi: 10.1111/j.1478-3231.2007.01586.x.
BACKGROUND/AIMS: Primary biliary cirrhosis (PBC) is characterised by the presence of immunoglobulin (Ig) G antimitochondrial antibodies (AMA), which are routinely detected by indirect immunofluorescence (IFL) using composite rodent tissue substrate. The IgG subclass distribution and clinical significance of IFL-detected AMA in patients with PBC have not been previously studied in detail.
We have examined IgG subclass-specific AMA detected by IFL on rodent liver, kidney and stomach tissue substrate using affinity-purified IgG subclass monospecific antisera as revealing reagents in 95 AMA-positive PBC patients from Greece.
AMA of any of the IgG1, IgG2 or IgG3 subclasses were present in 89/95 (93.7%) patients. Among those 89, 55 (61.8%) had IgG1, 2, 3 AMA positivity; eight (9%) had IgG1, 2; seven (7.9%) had IgG2, 3; eight (9%) had IgG1, 3; nine (10.1%) had IgG1 subclass and two (2.2%) single IgG3 AMA reactivity. IgG4 AMA was absent. IgG3 titres were higher than IgG2 and IgG1 (P<0.001) and IgG1 higher than IgG2 (P<0.001). IgG3 AMA-positive patients had a histologically more advanced disease (P<0.01) and were more frequently cirrhotic compared with those who were negative (P<0.01). There was a positive correlation between AMA IgG3 titre and Mayo risk score (r=0.55, P=0.009, Spearman's correlation).
Our findings suggest that AMA are not restricted to a specific IgG subclass. AMA of the IgG3 subclass are associated with a more severe disease course, possibly reflecting the peculiar ability of this isotype to engage mediators of damage.
背景/目的:原发性胆汁性肝硬化(PBC)的特征是存在免疫球蛋白(Ig)G抗线粒体抗体(AMA),通常使用复合啮齿动物组织底物通过间接免疫荧光法(IFL)进行检测。此前尚未对PBC患者中IFL检测到的AMA的IgG亚类分布及其临床意义进行详细研究。
我们使用亲和纯化的IgG亚类单特异性抗血清作为显色试剂,在来自希腊的95例AMA阳性PBC患者中,检测了在啮齿动物肝脏、肾脏和胃组织底物上通过IFL检测到的IgG亚类特异性AMA。
95例患者中有89例(93.7%)存在IgG1、IgG2或IgG3亚类中的任何一种AMA。在这89例患者中,55例(61.8%)IgG1、2、3 AMA呈阳性;8例(9%)IgG1、2呈阳性;7例(7.9%)IgG2、3呈阳性;8例(9%)IgG1、3呈阳性;9例(10.1%)IgG1亚类呈阳性,2例(2.2%)单一IgG3 AMA呈反应性。IgG4 AMA不存在。IgG3滴度高于IgG2和IgG1(P<0.001),IgG1高于IgG2(P<0.001)。与IgG3 AMA阴性患者相比,IgG3 AMA阳性患者的组织学疾病进展更严重(P<0.01),肝硬化的发生率更高(P<0.01)。AMA IgG3滴度与梅奥风险评分之间存在正相关(r=0.55,P=0.009,Spearman相关性)。
我们的研究结果表明,AMA不限于特定IgG亚类。IgG3亚类的AMA与更严重的疾病进程相关,这可能反映了该同种型参与损伤介质的特殊能力。